Genetic Technologies Ltd. (GENE)
| Market Cap | 67.32M |
| Revenue (ttm) | 6,803 |
| Net Income (ttm) | -4.21M |
| Shares Out | 4.16B |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $4.30 |
| Previous Close | $4.37 |
| Change ($) | -0.07 |
| Change (%) | -1.60% |
| Day's Open | 4.37 |
| Day's Range | 4.25 - 4.59 |
| Day's Volume | 476,354 |
| 52-Week Range | 1.45 - 5.67 |
MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with ...
MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, D...
MELBOURNE, Australia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market ...
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is devel...
MELBOURNE, Australia, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sale...
MELBOURNE, Australia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...
MELBOURNE, Australia, July 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, t...
Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.
MELBOURNE, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, t...
MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its in...
MELBOURNE, Australia, May 28, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, to...
MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, to...
MELBOURNE, Australia, May 22, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates:
MELBOURNE, Australia, May 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to p...
Temporary transition to high throughput COVID-19 testing Temporary transition to high throughput COVID-19 testing
MELBOURNE, Australia, April 06, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...
Genetic Tech (GENE) news for Wednesday includes GENE stock falling after the release of consumer tests for breast and colorectal cancer.
MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...
MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the ...
MELBOURNE, Australia, March 13, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,...
MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation bre...
MELBOURNE, Australia, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Labor...
MELBOURNE, Australia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an upda...
Genetic Technologies Limited (NYSE: GENE), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen.
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the comp... [Read more...]
| Industry Diagnostics & Research | Founded 1989 |
| CEO Dr. Jerzy Muchnicki MBBS | |
| Stock Exchange NASDAQ | Ticker Symbol GENE |
Financial Performance
In 2020, GENE's revenue was 9,864, a decrease of -61.23% compared to the previous year's 25,444. Losses were -6.10 million, -5.08% less than in 2019.